Krystal Biotech, Inc. (KRYS) Tops Q2 EPS by 7c, Beats on Revenue

Krystal Biotech, Inc. (NASDAQ: KRYS) reported Q2 EPS of $1.29, $0.07 better than the analyst estimate of $1.22. Revenue for the quarter came in at $96.04 million versus the consensus estimate of $92.24 million.

For earnings history and earnings-related data on Krystal Biotech, Inc. (KRYS) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• JPMorgan Downgrades Tata Technologies (TATATECH:IN) to Underweight
• Mizuho Starts Sol Gel Technologies Ltd. (SLGL) at Outperform